Osimertinib In EGFR Mutant Lung Cancer

Summary

This research study is studying a targeted therapy as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The names of the study drug involved in this study is: \- Osimertinib (Tagrisso)

Timeline

Start

2018-08-13

Primary completion

2028-02-28

Completion

2028-09-01

Drugs

Indications